BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home
»
Newsletters
» BioWorld MedTech
BioWorld MedTech
Nov. 16, 2015
View Archived Issues
Mindray merger a precursor to U.S. stock exchange delisting, return to private status
HONG KONG — One of the biggest Chinese medical device companies is undergoing a $3 billion delisting from the U.S. market as it paves the way to head back to its home market and the possibility of more access to investment.
Read More
CT colongraphy is again gaining traction on Hill
Read More
Mimedx says market overreacted to FDA's recent HCT/P guidance
Read More
Colombia defining technological device evaluation guidelines
Read More
M&A activity increases as industry gets personal
Read More
AHA, Google Life Sciences enter $50M research collaboration
Read More
Products
Read More
Thermo Fisher authorizes $1 billion share repurchase
Read More
Keeping you up to date on recent developments in Neurology
Read More
